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Abstract
Neuronal networks consist of different types of neurons that all play their own
role in order to maintain proper network function. The two main types of
neurons segregate in excitatory and inhibitory neurons, which together regulate
the flow of information through the network. It has been proposed that changes
in the relative strength in these two opposing forces underlie the symptoms
observed in psychiatric disorders, including autism and schizophrenia. Here,
we review the role of alterations to the function of the inhibitory system as a
cause of psychiatric disorders. First, we explore both patient and post-mortem
evidence of inhibitory deficiency. We then discuss the function of different
interneuron subtypes in the network and focus on the central role of a specific
class of inhibitory neurons, parvalbumin-positive interneurons. Finally, we
discuss genes known to be affected in different disorders and the effects that
mutations in these genes have on the inhibitory system in cortex and
hippocampus. We conclude that alterations to the inhibitory system are
consistently identified in animal models of psychiatric disorders and, more
specifically, that mutations affecting the function of parvalbumin-positive
interneurons seem to play a central role in the symptoms observed in these
disorders.
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Introduction
Psychiatric disorders, including autism, schizophrenia, bipolar dis-
order, attention deficit hyperactivity disorder (ADHD) and depres-
sion, affect millions of people and are a major socio-economic 
burden1–3. The identification of underlying genetic defects and 
risk factors is becoming increasingly efficient because of genome-
wide interrogation methodologies, yet owing to the complex mul-
tifactorial origin of most cases, a conclusive molecular diagnosis 
is made for only a minority of patients. Therefore, the underly-
ing causes for these conditions are poorly understood, and often 
treatment is still based on symptomology4–6. In 2003, Ruben-
stein and Merzenich proposed autism spectrum disorders (ASDs) 
to be caused by an increase in the ratio between excitation and 
inhibition, called the E/I balance7. Since then, this hypothesis 
has been substantiated by a vast number of studies and also has 
been implicated in other psychiatric disorders such as schizo-
phrenia8, consistent with their partially overlapping phenotypes9. 
Recently, the focus has shifted to changes to the inhibitory side of 
the E/I balance10,11, in particular to one class of inhibitory neurons, 
parvalbumin (PV)-positive interneurons12. In this review, we 
focus on the role of the inhibitory system in psychiatric disor-
ders and explore the changes to the inhibitory systems in different 
disorders. We then discuss the role and function of PV interneu-
rons and highlight the changes to this specific class of interneurons 
in the various psychiatric disorders.
Evidence for inhibitory dysfunction in psychiatric 
disorders
Since Rubenstein and Merzenich postulated their hypothesis 
of a reduced E/I balance in ASDs, there has been an increasing 
amount of evidence for disrupted inhibitory control in psychiatric 
disorders. This evidence comes from post-mortem studies and stud-
ies of patient phenotypes.
Firstly, post-mortem studies on patient brains have revealed 
consistent changes to the inhibitory system in various disorders. 
Studies of autistic brains revealed reduced expression of the 
gamma-aminobutyric acid (GABA) synthesizing enzymes GAD65 
and GAD67, as well as various GABA receptor subunits, in pari-
etal cortex and cerebellum13,14. In schizophrenia, reductions of 
interneuron markers have been found in the prefrontal cortex15–18, a 
region strongly implicated in this condition19. Interestingly, in recent 
years, this reduction has been shown to be caused by a reduction of 
the expression of the interneuron markers rather than a reduction 
of the number of interneurons20–22, which indicates reduced activ-
ity of these neurons23–25. In addition, both increased and decreased 
numbers of specific interneuronal subtypes are reported in bipo-
lar disorder17,26, while a reduced inhibitory function is reported in 
depression27,28 and bipolar disorder29.
Secondly, patients with psychiatric disorders display phenotypes 
that are strongly correlated to impaired inhibition. Epilepsy is a 
common comorbidity with psychiatric disorders and has consist-
ently been linked to impaired inhibitory function30–33. In patients 
with autism, it is estimated that the prevalence of epilepsy comor-
bidity is around 25%34,35. However, this is dependent on the type 
of autism, and the prevalence can be as high as 80% in Rett 
syndrome36, a monogenic form of autism caused by mutation in 
the MeCP2 gene37. It is currently unclear whether schizophrenia is 
a risk factor for epilepsy. A limited number of studies have been 
dedicated to this question, and contradicting results have been 
reported38,39. However, patients with epilepsy show an increased 
risk of schizophrenia or schizophrenia-like psychosis40. Likewise, 
patients with epilepsy show an increased risk for ADHD41,42.
Another recurrent phenotypic change is the altered power of 
gamma oscillations, as measured with electroencephalography or 
magnetoencephalography in humans, indicating changes in neuro-
nal synchrony43. Gamma oscillations are important for integration 
of information in neuronal circuits and have been linked to various 
functions, including attention44 and memory45. It was shown that 
PV-positive interneurons46, specifically PV-positive basket cells 
(see below), play an important role in these osciliations43,47,48. 
Changes in gamma oscillations are consistently found in patients 
with schizophrenia49, affecting different regions, including the pre-
frontal cortex50,51. Interestingly, while a decrease in gamma power 
is linked to negative symptoms of this disorder, such as psychomo-
tor poverty52, increased gamma power has been observed during 
positive symptoms, such as hallucinations53. In addition, compu-
tational studies suggest a central role for inhibitory synaptic scal-
ing in maintaining a stable neuronal network54 and found changes 
in inhibitory transmission to be sufficient to explain the changes 
in gamma oscillations in schizophrenia55. Together, altered inhibi-
tory control is believed to lead to a change in the power of gamma 
oscillations, which play a central role in schizophrenia56.
Though studied mainly in schizophrenia, changes in gamma oscil-
lations have been observed in other psychiatric disorders, includ-
ing autism, ADHD and bipolar disorder57–63. For example, children 
with autism show a reduced gamma frequency modulation to a 
visual task64, whereas in ADHD, increased power and synchrony 
were observed59–62. Together, post-mortem and patient studies 
point to an important role for altered inhibitory function in various 
psychiatric disorders and indicate a vital role for inhibition in the 
maintenance of the E/I balance in the healthy brain.
The central role of parvalbumin-positive interneurons 
in E/I balance
Cortical and hippocampal synaptic inhibition is mediated by 
inhibitory interneurons, most of which use GABA as their neuro-
transmitter. While interneurons make up around 20% of the total 
neuronal population, they are highly diverse65,66. For example, 
different classes of interneurons are specialized to target the den-
drites, soma or axon initial segment (AIS) of pyramidal neurons65. 
This large variety of cell types is believed to illustrate the distinct 
functions that these cells have in regulation of the network67. 
Cortical interneurons can be segregated in three non-overlapping 
groups by means of specific markers: PV, somatostatin (SOM) and 
the serotonin receptor 3a (5HT3aR), accounting for 40%, 30% and 
30% of the total interneuron population, respectively68. 5HT3aR-
positive cells mainly originate from the caudal ganglionic eminence 
and are further divided as vasoactive intestinal peptide (VIP)- 
positive and VIP-negative interneurons68. VIP-positive interneu-
rons mainly inhibit other interneurons and play an important role 
in disinhibition of the local circuit69, where they receive excitatory 
input from other cortical areas70,71. VIP cells mainly inhibit SOM 
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cells72 but also target PV interneurons23 and are involved in the reg-
ulation of the behavioural state of the network71,73. Recent studies 
have suggested a direct inhibition by VIP interneurons of pyrami-
dal cells in cortex74,75. Despite the prominent, mainly disinhibitory, 
function of VIP cells in the network, only a limited number of 
studies have implicated VIP cells to be involved in psychiatric 
disorders26,76.
SOM interneurons are a diverse class of interneurons originating 
from the medial ganglionic eminence (MGE)68. These interneurons 
target non-SOM interneurons72 as well as the dendritic domain of 
pyramidal neurons, including dendritic spines77. SOM interneu-
rons regulate the integration of local excitatory input78,79 and have 
been shown to regulate synaptic plasticity via the control of den-
dritic calcium spikes in pyramidal cells, affecting learning tasks80. 
Increasing evidence implicates SOM interneurons in psychiatric 
disorders. Disinhibition of SOM interneurons leads to an anti-
depressive–like phenotype in mice81, and reduced levels of SOM 
in cerebral spinal fluid have been linked to major depression and 
mood disorders82. In addition, a recent article shows a role for SOM 
interneurons in gamma oscillations in the visual cortex83, hinting 
towards a possible role for SOM interneurons in the changes in 
gamma oscillations observed in psychiatric disorders.
PV interneurons are MGE-derived and are electrophysiologically 
identified by their fast-spiking phenotype. Although PV interneu-
rons make up only a small part of the entire neuronal population84,85, 
these interneurons are strongly implicated in psychiatric disorders 
and have been shown to play an important role in the regulations 
of the E/I balance8,10,86. PV interneurons are involved in gamma 
oscillations (see above), and various mutations in disease-linked 
genes affect PV interneuron function (discussed below) (Table 1). 
Different subtypes of PV interneurons are distinguished: basket 
cells, chandelier cells, bistratisfied cells, and, in hippocampus, 
oriens-alveus-lacunosum-moleculare cells87,88 form the largest of 
these groups, the first two of which are most widely studied. Here, 
we will discuss both types and focus on their respective roles in the 
network.
PV basket cells
Basket cells are the largest group of PV interneurons and spe-
cifically target the soma and proximal dendrite of pyramidal 
neurons87. The perisomatic location of these axon terminals allows 
PV basket cells to have a strong control over the excitability of 
pyramidal neurons. Among other cortical inputs, PV basket cells 
receive the same excitatory input as their pyramidal cell targets, wir-
ing the basket cell into a feed-forward circuit: excitatory input will 
excite both the PV basket cell and the pyramidal neuron, followed 
by the PV basket cell inhibiting the pyramidal neuron. The delay 
between the excitatory and inhibitory input onto the pyramidal cell 
creates a coincidence detection window, in which excitatory input 
can summate to elicit an action potential in the pyramidal cell89. 
If inhibitory input arrives at the pyramidal cell before an action 
potential is evoked, the somatic targeted GABA action will prevent 
action potential initiation. So PV basket cells allow action potential 
initiation in pyramidal neurons only if the excitatory information 
is time-locked and of sufficient strength.
In order to mediate fast inhibition, PV basket cells are optimized 
for fast signalling85. Action potentials are initiated at the AIS and 
propagate at high velocities through the axon90 which is enriched 
for the fast sodium channel NaV1.191. Synaptically, calcium inflow 
is mediated by fast P/Q-type calcium channels92, which are located 
directly adjacent to the release site93. The post-synaptic site, on the 
pyramidal neuron, contains the fast GABAAα1 receptor subunit94. 
These fast properties ensure an optimal speed of PV basket cell 
signalling and tightly regulate coincidence detection windows of 
pyramidal neurons.
Chandelier cells
Chandelier cells, or axo-axonic cells, are a group of interneurons 
that target the AIS of pyramidal neurons95,96. These cells form 
vertically oriented clusters of axon terminals, called cartridges, 
giving them a chandelier-like appearance. A single pyramidal 
cell receives contacts from multiple chandelier cells97, forming an 
average of 3 to 5 boutons each98 depending on the brain region99 
and age100. The synapses are enriched for the GABAAα2 receptor 
subunit101,102 and pre-synaptically express the high-affinity GABA 
transporter 1 (GAT1)103. The function of chandelier cells in the 
network remains largely unknown. However, chandelier cell 
activity has been shown to increase with increasing network 
activity104. In addition, the axon terminals of chandelier cells are 
specifically absent from the epileptic focus105,106, and pharmaco-
logical induction of seizures leads to a loss of chandelier cells in 
rats107, suggesting a role in preventing excessive excitatory activity 
in the network for these interneurons104.
Since their discovery, there has been a debate about the actions of 
chandelier cells (reviewed by Wang and colleagues98). Some stud-
ies using brain slice recordings showed a depolarizing108 and even 
excitatory109 action for these interneurons, whereas others report an 
inhibitory action110. However, chandelier cell membrane potential 
fluctuations resembling in vivo patterns appear strongly inhibi-
tory111, and recordings in vivo also suggest an inhibitory role for 
these interneurons112,113.
Whereas patient studies of schizophrenia patients consistently 
identify both a reduction in the number or length of chandelier 
cell cartridges114,115 as well as the misregulation of proteins associ-
ated with chandelier cell synapses12,116–118, mouse research on this 
interneuron class is hampered by the absence of a strategy to spe-
cifically target these interneurons. As a result, a limited number of 
studies focus on chandelier cells but instead report on PV interneu-
rons in general, or PV basket cells, which provide a more acces-
sible target of study because of their relative abundance (Figure 1). 
Nonetheless, chandelier cells are considered to play an impor-
tant role in psychiatric disorders11,98,119, and the development of 
strategies to specifically target this interneuron subtype would 
be an important step towards understanding the role of these 
interneurons.
Targeting the perisomatic region (basket cells) or AIS (chandelier 
cells) gives these interneurons strong control over pyramidal 
cell excitability, and regulation of the synaptic strength of these 
interneurons is important for normal function of the network. For 
Page 4 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
Table 1. Genes linked to psychiatric disorders affect distinct subcellular aspects.
Aspect Gene Syndrome/Disorder Model Investigated 
region
Phenotype Reference
Input Erbb4 SZ PV interneuron KO Hippocampus Reduced excitatory input to PV 
basket cells and chandelier cells
120
Nrg1 SZ NRG1 treatment of 
dissociated cortical 
cultures
Cortical 
(cultures)
Increased excitatory synapse 
number onto interneurons
121
Fmr1 Fragile X syndrome; 
ASD
Fmr1 KO mouse Cortex Reduced local excitatory input 
onto FS interneurons
122
DISC1 SZ, ASD, depressive 
disorder, BD
PV-specific shRNA 
KD in vivo
Cortex Increased excitatory input onto PV 
interneurons
123
Nlgn3 ASD PV interneuron KO Hippocampus 
Hippocampus
Decreased NMDAR responses 
Increased glutamate release onto 
PV interneurons
124
Mecp2 Rett syndrome; ASD PV interneuron KO Cortex Reduced local excitatory input 
onto PV interneurons
125
Intrinsic Mecp2 Rett syndrome; ASD PV interneuron KO Cortex Increased intrinsic excitability of 
PV interneurons
125
Dysbindin SZ Dysbindin KO mouse Cortex Reduced excitability of FS 
interneurons
126
Scn1a Dravet syndrome; 
ASD
Scn1a KO mouse Hippocampus Impaired action potential kinetics 
in interneurons
127
Shank3 ASD, SZ Shank3B KO mouse Cortex, Striatum Reduced activity of PV 
interneurons
22
Output Erbb4 SZ PV interneuron KO Hippocampus Reduced cartridges from 
chandelier cells onto pyramidal 
neurons
120
Nrg1 SZ Overexpression in 
pyramidal neurons
Cortex Increased basket cell and 
chandelier cell boutons onto 
pyramidal neurons
128
Tsc1 Tuberous sclerosis; 
ASD
Sparse Tsc1 deletion 
in CA1 pyramidal 
neurons
Hippocampus Reduced inhibitory synaptic 
strength onto pyramidal neurons
129
Ube3a Angelman syndrome; 
ASD
Maternal loss of 
Ube3a mouse
Cortex Reduced inhibitory drive from FS 
and non-FS interneurons onto 
pyramidal neurons
130
Shank3 ASD, SZ Shank3-exon9 KO 
mice
Cortex Reduced inhibitory input onto 
pyramidal neurons
131
Shank3-exon9 KO 
mice
Hippocampus Increased inhibitory input onto 
pyramidal neurons
131
Git1 ADHD Git1 KO mouse Hippocampus Reduced inhibitory inputs onto 
pyramidal neurons
132
Cdh13 ADHD Cdh13 KO mouse Hippocampus Increased number of inhibitory 
synapses onto pyramidal neurons 
133
Nlgn 2 ASD Nlgn2 KO mouse Cortex Reduced inhibitory drive onto 
pyramidal neurons from FS 
interneurons
134
ASD Nlgn2 KO mouse Hippocampus Reduced number of perisomatic 
synapses onto pyramidal neurons
135
Nlgn 3 ASD Nlgn3 R451C mouse Hippocampus Reduced inhibitory drive from 
PV basket cells onto pyramidal 
neurons
136
Cntnap2 ASD shRNA KD in 
dissociated cortical 
cultures
Cortical 
(cultures)
Reduced inhibitory drive onto 
pyramidal neurons
137
ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; BD, bipolar disorder; FS, fast-spiking; KD, knockdown; KO, knockout; PV, 
parvalbumin-positive; shRNA, short hairpin RNA; SZ, schizophrenia. Page 5 of 16
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example, Xue and colleagues have shown that pyramidal neurons 
receive an amount of synaptic inhibition that is proportional to 
the amount of synaptic excitation they receive138, maintaining the 
E/I balance on the pyramidal cell. Manipulation of pyramidal cell 
activity leads to a compensatory change in inhibitory drive onto 
these cells, specifically from PV interneurons138. In addition, PV 
interneuron activity is reduced during learning and increased 
during fear conditioning, and an experimental increase of PV 
interneuron activity leads to impaired learning23. Apart from synaptic 
connections, basket cells139 and chandelier cells111,140 connect via 
electrical connections, called gap junctions. This electrical coupling 
synchronizes the interneurons139, which in turn allows them to syn-
chronize the network141 (for example, in gamma oscillations142).
Together, these studies indicate that control of the E/I balance by 
PV interneurons is important for normal network function and that 
PV interneuron-mediated inhibition can be regulated upon altera-
tions in the network state. Changes in PV interneuron-mediated 
inhibition would shift the E/I balance and lead to a disruption in 
network function. Indeed, various parameters affecting inhibitory 
function of PV cells are consistently found to be altered in psy-
chiatric disorders. In the next section, we focus on studies on 
animal models of these conditions and discuss how different 
changes affecting PV cell activity lead to a shift of the E/I balance 
(Table 1).
Altered PV interneuron activity is caused by changes 
to different subcellular aspects
Alterations to the inhibitory drive, affecting the E/I balance, 
can arise in different ways. Reduced excitatory input onto 
interneurons, reduced intrinsic excitability of interneurons, 
and a reduction in inhibitory synapse number or strength onto 
pyramidal cells all result in a shift of the E/I balance towards exci-
tation. Indeed, patient and animal studies of psychiatric disorders 
consistently report changes affecting inhibitory function. A com-
plicating factor in the interpretation of these results comes from the 
dynamic ability of neuronal networks to adapt to changes, known 
as homeostatic plasticity. Homeostatic plasticity is the ability of 
neurons to maintain their levels of excitability within a narrow 
range and is a constantly active feedback process143. For example, 
classic experiments have shown that blocking of action poten-
tials leads to a strengthening of excitatory144 and a weakening of 
inhibitory synapses145. Apart from their synaptic input, neurons can 
regulate their intrinsic excitability146, which is observed both in 
excitatory and inhibitory neurons in culture147 and in vivo148. This 
means that genetic mutations affecting a specific neuronal prop-
erty in a specific cell type can trigger homeostatic processes affect-
ing other properties or cell types. In this way, mutations affecting 
both inhibitory or excitatory cells could ultimately affect inhibitory 
function86. It is therefore difficult to distinguish the direct effect of 
a gene related to a psychiatric disorder from the network adaptation 
it causes.
Nonetheless, changes to the function of PV interneurons, either 
direct or indirect, are consistently observed in psychiatric 
disorders affecting input, output and intrinsic properties, which all 
lead to an altered inhibitory action of these cells onto their targets 
(Figure 1).
Changes to the input onto PV interneurons
Excitatory inputs onto neurons drive their excitability. Depend-
ing on the brain region, PV interneurons receive various types of 
Figure 1. Genes linked to psychiatric disorders affect inhibition on different subcellular aspects. (Left) Genes affecting the input, 
intrinsic properties or output of chandelier cells. (Right) Genes affecting the input, intrinsic properties or output of parvalbumin-positive (PV) 
basket cells. (Middle) Genes affecting input, intrinsic properties or output of interneurons, without the interneuron subtype being identified. 
Pyramidal cells are shown in red, and interneurons are shown in blue.
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excitatory input85, and the amount of excitatory inputs onto PV 
interneurons is dynamically regulated by behaviour23. Changes 
in the amount of excitation onto PV interneurons, altering their 
activity, have been reported in mouse models of various psychiatric 
disorders.
The tyrosine kinase receptor ErbB4 has been identified as a risk 
gene for schizophrenia in genome-wide association studies 
(GWASs)149,150. In the adult mouse, expression of ErbB4 is restricted 
to interneurons128,151 and localizes to both the axon terminals128,152 
and post-synaptic densities128,151. Selective removal of ErbB4 from 
PV interneurons causes a reduction in excitatory synapses formed 
onto both PV basket cells and chandelier cells as well as a reduced 
number of PV synapses formed on pyramidal neurons120,121. This 
reduced input and output connectivity of PV interneurons is indic-
ative of a reduced inhibitory drive onto pyramidal neurons. As a 
result of this reduced inhibition of the pyramidal neurons, these 
neurons become more active, as was seen from the increased 
frequency of excitatory inputs to both pyramidal neurons and 
PV interneurons120. Consequently, recording of the local field 
potential in vivo revealed a hyperactive network and increased 
gamma  oscillations120. Single-nucleotide polymorphisms in neu-
regulin 1 (NRG1), a ligand of ErbB4, have been implicated in 
schizophrenia153  and bipolar disorder154,155. Treatment of neuro-
nal cultures with NRG1, activating ErbB4, leads to an increase in 
excitatory synapses formed onto interneurons121. Together, these 
data show that ErbB4 signalling plays an important role in the 
regulation of excitatory synapse number onto PV interneurons and 
that disruption of this system leads to a shift of the E/I balance 
towards excitation120.
Also, studies on animal models of ASD have reported postsynap-
tic changes on PV interneurons. Fragile X syndrome is caused by 
reduced or absent levels of the RNA-binding protein FMRP, leading 
to intellectual disability and, in about half of the affected males, 
ASD156,157. While changes to long-term depression on excitatory 
cells have been the centre of attention for this condition158, changes 
to the inhibitory system have consistently been identified159,160. 
Fmr1 knockout (KO) mice show a reduced expression of GABAA 
receptor subunits161 as well as a reduction in the number of PV 
interneurons162. In addition, these mice show a marked reduc-
tion in local, but not thalamic, excitatory input onto fast-spiking 
interneurons in layer 4 of the somatosensory cortex, while both the 
connectivity of fast-spiking interneurons onto pyramidal neurons 
and excitatory inputs onto pyramidal neurons were unaltered122. 
Consistently, the resulting reduced inhibitory drive from fast-
spiking interneurons was accompanied by reduced synchrony of 
gamma oscillations122. These changes point towards an altered E/I 
balance towards excitation in fragile X syndrome163.
Mutations in another gene linked to autism, the transcriptional 
modulator methyl-CpG-binding protein 2 (MECP2), the causative 
gene for Rett syndrome37, show a similar phenotype. Selective 
removal of Mecp2 from PV cells leads to a specific reduction of 
local excitatory input, but not thalamocortical input, onto these 
cells in layer 4 of the visual cortex at post-natal day (P) 30125. 
In addition, experimentally evoked PV interneuron input onto 
pyramidal cells was unaltered125. Calcium imaging revealed that 
these synaptic changes lead to a reduced visually evoked, but not 
spontaneous, activity of PV interneurons125. Paired recordings at 
P15 revealed an increased inhibition from PV interneurons through 
an earlier maturation in Mecp2 KO mice164, and this earlier matu-
ration might influence network development through interfer-
ence with the normal critical period164,165, leading to the changes 
observed at later ages. This notion is consistent with the recent 
idea that developmental changes might play an important role in 
the development of psychiatric symptoms later in life166. The exact 
contribution of PV interneurons to the phenotypes observed in Rett 
syndrome is still unclear. While a general interneuron removal of 
Mecp2 does recapitulate most Rett syndrome phenotypes167, stud-
ies removing Mecp2 specifically from PV interneurons have been 
able to replicate only some of these phenotypes168 or none at all125. 
Of note, selective removal of Mecp2 from SOM interneurons also 
recapitulates part of the Rett syndrome phenotypes168, and selective 
removal of Mecp2 from either PV interneurons or SOM interneu-
rons has been reported to cause circuit-wide deficits in information 
processing169. From these studies, a picture is emerging in which 
excitatory inputs onto PV interneurons are found to be altered in 
different psychiatric disorders, leading to a reduced activity of these 
neurons and thereby tilting the E/I balance towards excitation.
Changes to the intrinsic properties of PV interneurons
The intrinsic properties of neurons are important in translating 
input into output. Altering these properties allows the neurons to 
regulate their excitability170,171, through which they play an impor-
tant role in the maintenance of the E/I balance143. Whereas some 
of these changes might be causative to psychiatric disorders, 
others are believed to be compensatory. For example, selective 
deletion of Mecp2 from PV interneurons leads to an increased 
membrane potential, as well as a hyperpolarized action potential 
threshold in these cells at P30125, but only a slight hyperpolariza-
tion of the membrane potential at P15164. These changes increase 
the cell’s excitability and are most likely compensatory for the 
reduced excitatory synaptic input described above125 but could still 
act towards deficits in information processing observed in these 
animals169.
Family-based association data have identified dysbindin (DTNBP1) 
as a susceptibility gene for schizophrenia172, whose dominant cir-
cuit impact is impaired inhibition173. Dysbindin KO mice show a 
reduced number of PV interneurons in hippocampal CA1173,174, 
and transcriptome changes of various proteins involved the regula-
tion of intrinsic properties174. Recordings from PV interneurons in 
dysbindin KO mice show a reduction in action potential frequency 
resulting in a reduced inhibitory drive126. Interestingly, dopamine 
D2-receptor expression is increased in these mice, and application 
of the D2-receptor antagonist quinpirole increases PV interneuron 
action potential frequency more in dysbindin KO mice than in 
wild-type mice, suggesting that the changes in action potential 
frequency are compensatory126.
Intrinsic changes can also be the primary cause of psychiatric 
disorders. Single-gene mutations in SCN1A, encoding the sodium 
channel NaV1.1α subunit, give rise to Dravet syndrome, a rare 
genetic epileptic encephalopathy. Patients with Dravet syndrome 
suffer from epilepsy and have an increased risk for autism175,176. 
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NaV1.1 is enriched in the AIS of inhibitory neurons177, primarily of 
PV interneurons91, where axon potentials are initiated178. Interneu-
rons from Scn1a heterozygous and KO mice show reduced firing 
frequencies to current injections as well as a reduced action poten-
tial amplitude and an increased action potential width, indicating a 
reduced inhibitory control over downstream targets127. Removal of 
Scn1a specifically from forebrain interneurons179 or PV interneu-
rons specifically180 recapitulates phenotypes found in patients. 
In addition, increasing GABA signalling by application of the 
positive allosteric GABAA receptor modulator clonazepam was 
sufficient to rescue the abnormal social behaviour in Scn1a+/− 
mice181. These data show that loss of SCN1A primarily affects 
interneurons and that the consequently reduced inhibitory drive 
plays an important role in Dravet syndrome.
Recently, a new hypothesis has been proposed in the field of 
schizophrenia, focussing on the myelination of PV interneurons 
as a point of pathological convergence182. As discussed above, PV 
cells play a central role in schizophrenia. Myelination abnormali-
ties, including white matter abnormalities183, reduced numbers of 
oligodendrocytes184 and post-mortem gene expression analysis185, 
have been identified in schizophrenia. Myelination of PV interneu-
rons has been observed in rats186, mice187 and post-mortem in 
humans188. Myelination is important for fast action potential 
propagation189, and deficits in the myelination of PV interneurons 
are proposed to disrupt inhibitory network function182. However, 
this appealing hypothesis remains to be experimentally tested.
Changes to synapses formed by PV interneurons
Changes to PV synapses are abundantly studied and identified in 
various conditions. Post-mortem studies of schizophrenia patients 
consistently identify changes to the cartridges formed by chande-
lier cells, showing a decrease in pre-synaptic GAT1 expression116,117 
and an increase in the expression of post-synaptic GABAAα2118. 
These changes would lead to an increased inhibitory drive from 
chandelier cells and are believed to be compensatory for a reduced 
activity of these cells, as indicated by reduced levels of GAD67 in 
PV cells190. In addition, a recent study shows a reduction in the den-
sity of a specific type a cartridges, calbindin-positive cartridges, in 
schizophrenia114.
Besides changes in the input to PV interneurons, mutations in Erbb4 
also lead to a reduction in synapses formed by PV interneurons on 
pyramidal neurons, specifically from chandelier cells120,128. In addi-
tion, overexpression of Nrg1, the ligand for ErbB4, in pyramidal 
neurons increases bouton density on both the AIS and the soma 
of pyramidal neurons. The increase in bouton density on the AIS 
originates from chandelier cells since only these cells target the 
AIS. The origin of the increase in perisomatic bouton density is 
not clear since a recent report has shown that synapses formed by 
cholecystokinin (CCK) basket cells require ErbB4 function to form 
perisomatic synapses191. Future research should unveil whether the 
increase in perisomatic boutons density arises from PV or CCK 
basket cells.
Tuberous sclerosis is a disorder whose symptoms include epilepsy 
and autism192. Loss-of-function mutations in the mammalian target 
of rapamycin (mTOR)-negative regulators TSC1 or TSC2 
underlie this condition193. Slice recordings from TSC1 KO neurons 
revealed a reduced inhibitory drive onto CA1 pyramidal neurons, 
while excitatory input was unaltered129. TSC1 KO neurons were 
created by sparsely targeting neurons in a conditional TSC1 KO 
mouse with a cre-expressing adeno-associated virus129. The find-
ing that sparse KO of TSC1 leads to a similar phenotype as in 
neurons from full KO animals indicates that these results are cell- 
autonomous rather than compensatory129.
Angelman syndrome, caused by loss-of-function mutations or 
deletion of E3 ubiquitin ligase UBE3A194, is characterized by epi-
lepsy and autism195,196. Mouse models for Angelman syndrome 
recapitulate human phenotypes197 and initially were found to 
show a reduced excitatory drive onto pyramidal neurons198. 
However, inhibitory input was also found to be decreased, caused 
by defects in synaptic vesicle cycling130. It was hypothesized that 
the reduced inhibition could outweigh the reduced excitation, 
leading to the epilepsy and autism phenotypes obeserved130,199. 
Consistent with this idea, a recent study using in vivo whole cell 
recordings shows that pyramidal neurons in Ube3a KO mice 
display decreased orientation selectivity200, indicative of reduced 
inhibition201,202. However, these mice also show increased 
excitability of pyramidal neurons, which is non–cell-autonomous, 
suggesting that pyramidal neurons homeostatically increase their 
excitability because of a relative decrease of excitation200. While 
it is unclear whether reduced inhibition or reduced excitation has 
a stronger impact on pyramidal neurons in Angelman syndrome, 
the change in their relative contribution, resulting in an altered E/I 
balance, seems to play a pivotal role in this condition.
Single SHANK3 mutations, at the level of point mutations or 
microdeletions, have been identified in patients with ASD203. In 
the human genome, there are three SHANK genes (SHANK1-3), 
which all code for scaffold proteins located at the postsynap-
tic density of excitatory synapses, of which SHANK3 is best 
studied204–206. Because of this localisation, most studies have 
focussed on excitatory synapses, where Shank3-deficient mice 
show reduced cortico-striatal connectivity207, impaired long-term 
potentiation208 and reduced GluA1 expression209. Recent studies, 
however, indicate that the inhibitory system is also affected. Shank3 
mutant mice lacking exon 9 show reduced inhibitory input onto 
layer 2/3 pyramidal neurons but an increase of these events in 
CA1 pyramidal neurons131. In addition, PV levels are reduced in 
Shank1 KO and Shank3b KO mice, indicating reduced activity22.
Presynaptic neurexins and their postsynaptic partners neuroligins 
are a large class of cell-adhesion molecules that have been shown 
to play important roles in synaptic specificity210. Overexpression 
or knockdown of neuroligins leads to an increase or decrease in 
synapse number, respectively211. Neuroligins are expressed at spe-
cific synapses: neuroligin 1 (NLGN1) is mainly expressed at exci-
tatory synapses212, NLGN2 is expressed at inhibitory synapses213, 
NLGN3 is expressed at both inhibitory and excitatory synapses214 
and NLGN4 is expressed at glycinergic synapses215. Mutations and 
deletions affecting human NLGN3, including a gain-of-function 
mutation, and NLGN4 de novo mutations have been found 
in Swedish families and have been associated with autism216. 
Nlgn3 deletion in mice leads to increased inhibitory transmission 
onto pyramidal neurons217, specifically from CCK-positive 
interneurons because of an increased tonic endocannabinoid 
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signalling, whereas PV interneuron connectivity is unaffected136. 
A recent study, however, has shown that conditional deletion 
of Ngln3 from PV interneurons alters AMPA/NMDA (alpha-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid/N-methyl- 
d-aspartate) ratio of excitatory input onto these cells and causes 
reduced gamma oscillations124. In addition to the loss of NLGN3, 
a gain-of-function amino acid substitution (R451C) in NLGN3 
is associated with autism216. Mice carrying this mutation show a 
strong reduction in inhibitory drive from PV interneurons while 
increasing the inhibitory drive from CCK cells136.
Nlgn4 KO mice show a reduced number of perisomatic inhibitory 
synapses in hippocampus and a concomitant reduction in inhibitory 
input218. In addition, a reduced power of evoked gamma oscilla-
tions in acute slices was observed218. Different mutations in NLGN2 
have been linked to autism219 and schizophrenia220. Deletion of 
Nlgn2 has been shown to specifically reduce the amount of peri-
somatic synapses on pyramidal neurons in hippocampus135 and 
reduce inhibitory transmission from PV interneurons but not SOM 
interneurons134.
Neurexins are less well studied in the context of psychiatric 
disorders. There are three neurexin genes, each coding for an 
α- and β-neurexin. Mutations in neurexin (NRXN1) have been 
associated with autism221 and schizophrenia, affecting both 
NRXN1α and NRXN1β222,223. Nrxn1α KO mice do not show changes 
in inhibitory drive but do show a reduced excitatory drive onto 
CA1 pyramidal neurons224. However, mice carrying mutations in 
Nrxn1β show a reduced frequency of both inhibitory and exci-
tatory input onto cortical pyramidal neurons225 suggestive of a 
reduced number of synaptic contacts. These studies show that neu-
roligin and neurexin mutations that are linked to autism affect the 
inhibitory system, including perisomatic-targeting interneurons.
Studies of ADHD rodent models have mainly focussed on the 
dopamine system and excitatory synapses226. However, recent 
studies identify changes to inhibitory connectivity. G protein– 
coupled receptor kinase interacting protein 1 (GIT1) has been 
identified by a GWAS as a risk gene for ADHD132, but recent 
studies challenge this claim227,228. Git1 KO mice show ADHD-
like phenotypes, including hyperactivity132. While excitatory input 
to CA1 pyramidal neurons remains unaltered, the frequency 
of inhibitory inputs is reduced, suggesting a reduction of inhibi-
tory synaptic contacts132, consistent with previous studies 
showing a role for GIT1 in inhibitory synapses229. In addition, 
PV expression was reduced while other interneuron markers 
remained unaltered132.
Another ADHD-linked gene identified by GWASs, cadherin 13 
(CDH13)230–232, is exclusively expressed in inhibitory neurons133. 
Cdh13 KO mice show an increase in inhibitory synaptic contacts 
onto CA1 pyramidal neurons, while excitatory inputs remained 
unaltered133. This increase in inhibitory synaptic contacts could 
underlie the increase in gamma oscillations observed in ADHD 
patients discussed before59–62. Cdh13 KO mice show a reduced 
number of interneurons at embryonic day 18.5233 but not at P21133. 
Experiments are needed to test whether the changes in interneuron 
number have a role in the aetiology of ADHD.
In addition to changes in the number and strength of inhibitory 
synapses, changes are found in the modulation of inhibitory syn-
aptic transmission. Metabotropic GABA receptors, GABAB recep-
tors, are expressed both pre- and postsynaptically in GABAergic 
synapses234. Postsynaptic GABAB receptors activate potassium 
channels that hyperpolarize the postsynaptic cell235. Presynap-
tic GABAB receptors, in addition, can reduce calcium inflow 
and reduce neurotransmitter release236,237. A reduction of GABAB 
subunit expression has been observed in post-mortem studies of 
patients with schizophrenia238,239, patients with bipolar disorder240 
and patients with major depression241 as well as animal models for 
schizophrenia242–244. However, more research is required to identify 
the exact role for GABAB receptors in psychiatric disorders.
In summary, changes to the inhibitory drive of PV interneurons 
can be caused by changes affecting the input, output or intrin-
sic properties of PV interneurons, and animal models of various 
psychiatric disorders all show alterations to one or more of these 
aspects, tilting the E/I balance.
Conclusions
Psychiatric disorders are a diverse group of disorders, but changes 
to the inhibitory system seem to be a point of convergence. 
Impairment of normal inhibitory function can arise from input to, 
output from, or intrinsic properties of inhibitory neurons. Altered 
inhibitory activity or drive leads to changes in signal processing, 
which in turn is believed to underlie the phenotypic changes 
observed in the various psychiatric disorders. PV-positive interneu-
rons play a pivotal role in these conditions, possibly through 
their strong inhibitory effect on pyramidal cell activity due to the 
axonal or perisomatic targeting of their axons in combination 
with the nature of their functions in the network.
Changes to either excitation or inhibition will change the ratio 
between these two types of input, leading to a change in the E/I 
balance. The examples described above indicate that various psy-
chiatric disorders occur following changes to the input, output 
or intrinsic properties of specific interneurons, PV interneurons, 
leading to an altered activity of these neurons. It seems from the 
studies discussed that specific changes in the E/I balance lead to a 
disruption of specific function(s) in the network that affect signal 
processing in a specific way to result in a specific psychiatric phe-
notype. This might explain why different disorders present different 
phenotypes, in both patients and animal studies. For example, 
changes in chandelier cell cartridges seem to be more prominent 
in schizophrenia. However, other factors are likely to contribute to 
the development of a specific disorder. Apart from the affected PV 
cell type, the direction of the altered activity (increased/decreased 
E/I balance) might be an important factor. Another interesting 
aspect might be the changes in interneuron-interneuron connec-
tivity, which could lead to altered signal integration and network 
activity. Some genes have been associated with multiple psychi-
atric disorders, indicating that a mutation does not in all cases 
lead to a specific condition. Individual difference in compensatory 
plasticity could subtly affect network development, steering 
the developing network towards a specific disorder. It should be 
noted that while homeostatic changes might compensate a spe-
cific alteration, this compensation might disrupt other pathways. 
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While the above-mentioned factors potentially all play a role in the 
development of specific psychiatric disorders, more research is 
needed to identify how specific alterations to PV interneurons 
affect network processing and behaviour.
The notion that psychiatric disorders are caused by changes to the 
inhibitory drive from PV interneurons means that a restoration of 
this drive could improve patient symptoms. An interesting possi-
bility of counteracting the changes to the inhibitory system would 
be to make use of the neuron’s ability for homeostatic plasticity170. 
Homeostatic mechanisms function to keep neurons in an optimal 
range of activity245. Understanding which genetic and molecular 
mechanisms underlie these homeostatic processes opens the pos-
sibility to ‘hijack’ these pathways and manipulate the neuron’s 
activity in a way to compensate for the altered inhibitory drive. In 
this way, it might be possible to selectively up- or downregulate 
the activity levels of specific interneuron populations and thereby 
ameliorate the symptoms observed in patients with the various 
disorders.
While psychiatric disorders are still far from being fully under-
stood, the study of the role of the inhibitory system in these condi-
tions might further increase our understanding of both the diseased 
and the healthy brain and hopefully could lead to treatment or 
alleviation of the symptoms for those suffering from these 
conditions.
Competing interests
The authors declare that they have no competing interests.
Grant information
The author(s) declared that no grants were involved in supporting 
this work.
Acknowledgements
The authors would like to thank Wei Ba and Clémence Bernard for 
valuable discussions.
References F1000 recommended
1. Gore FM, Bloem PJ, Patton GC, et al.: Global burden of disease in young people 
aged 10–24 years: a systematic analysis. Lancet. 2011; 377(9783): 2093–102. 
PubMed Abstract | Publisher Full Text 
2. Lee FS, Heimer H, Giedd JN, et al.: Mental health. Adolescent mental health--
opportunity and obligation. Science. 2014; 346(6209): 547–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
3. Elsabbagh M, Divan G, Koh YJ, et al.: Global prevalence of autism and other 
pervasive developmental disorders. Autism Res. 2012; 5(3): 160–79.  
PubMed Abstract | Publisher Full Text | Free Full Text 
4. Remington G, Foussias G, Fervaha G, et al.: Treating Negative Symptoms in 
Schizophrenia: an Update. Curr Treat Options Psychiatry. 2016; 3(2): 133–50. 
PubMed Abstract | Publisher Full Text | Free Full Text 
5. Doyle CA, McDougle CJ: Pharmacologic treatments for the behavioral 
symptoms associated with autism spectrum disorders across the lifespan. 
Dialogues Clin Neurosci. 2012; 14(3): 263–79.  
PubMed Abstract | Free Full Text 
6. van Os J, Kapur S: Schizophrenia. Lancet. 2009; 374(9690): 635–45.  
PubMed Abstract | Publisher Full Text 
7.  Rubenstein JL, Merzenich MM: Model of autism: increased ratio of 
excitation/inhibition in key neural systems. Genes Brain Behav. 2003; 2(5): 
255–67.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
8. Gao R, Penzes P: Common mechanisms of excitatory and inhibitory imbalance 
in schizophrenia and autism spectrum disorders. Curr Mol Med. 2015; 15(2): 
146–67.  
PubMed Abstract | Publisher Full Text | Free Full Text 
9. Canitano R, Pallagrosi M: Autism Spectrum Disorders and Schizophrenia 
Spectrum Disorders: Excitation/Inhibition Imbalance and Developmental 
Trajectories. Front Psychiatry. 2017; 8: 69.  
PubMed Abstract | Publisher Full Text | Free Full Text 
10. Marín O: Interneuron dysfunction in psychiatric disorders. Nat Rev Neurosci. 
2012; 13(2): 107–20.  
PubMed Abstract | Publisher Full Text 
11.  Lewis DA, Hashimoto T, Volk DW: Cortical inhibitory neurons and 
schizophrenia. Nat Rev Neurosci. 2005; 6(4): 312–24.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
12. Lewis DA, Curley AA, Glausier JR, et al.: Cortical parvalbumin interneurons and 
cognitive dysfunction in schizophrenia. Trends Neurosci. 2012; 35(1): 57–67.  
PubMed Abstract | Publisher Full Text | Free Full Text 
13.  Fatemi SH, Reutiman TJ, Folsom TD, et al.: GABAA receptor downregulation 
in brains of subjects with autism. J Autism Dev Disord. 2009; 39(2): 223–30. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
14. Fatemi SH, Halt AR, Stary JM, et al.: Glutamic acid decarboxylase 65 and 67 kDa 
proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry. 
2002; 52(8): 805–10.  
PubMed Abstract | Publisher Full Text 
15. Beasley CL, Reynolds GP: Parvalbumin-immunoreactive neurons are reduced 
in the prefrontal cortex of schizophrenics. Schizophr Res. 1997; 24(3): 349–55. 
PubMed Abstract | Publisher Full Text 
16. Beasley CL, Zhang ZJ, Patten I, et al.: Selective deficits in prefrontal cortical 
GABAergic neurons in schizophrenia defined by the presence of calcium-
binding proteins. Biol Psychiatry. 2002; 52(7): 708–15.  
PubMed Abstract | Publisher Full Text 
17. Sakai T, Oshima A, Nozaki Y, et al.: Changes in density of calcium-binding-
protein-immunoreactive GABAergic neurons in prefrontal cortex in 
schizophrenia and bipolar disorder. Neuropathology. 2008; 28(2): 143–50. 
PubMed Abstract | Publisher Full Text 
18. Fung SJ, Webster MJ, Sivagnanasundaram S, et al.: Expression of interneuron 
markers in the dorsolateral prefrontal cortex of the developing human and in 
schizophrenia. Am J Psychiatry. 2010; 167(12): 1479–88.  
PubMed Abstract | Publisher Full Text 
19. Selemon LD, Zecevic N: Schizophrenia: a tale of two critical periods for 
prefrontal cortical development. Transl Psychiatry. 2015; 5: e623.  
PubMed Abstract | Publisher Full Text | Free Full Text 
20. Hashimoto T, Volk DW, Eggan SM, et al.: Gene expression deficits in a subclass 
of GABA neurons in the prefrontal cortex of subjects with schizophrenia.  
J Neurosci. 2003; 23(15): 6315–26.  
PubMed Abstract 
21.  Enwright JF, Sanapala S, Foglio A, et al.: Reduced Labeling of Parvalbumin 
Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of 
Subjects with Schizophrenia. Neuropsychopharmacology. 2016; 41(9): 2206–14. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
22.  Filice F, Vörckel KJ, Sungur AÖ, et al.: Reduction in parvalbumin expression 
not loss of the parvalbumin-expressing GABA interneuron subpopulation 
in genetic parvalbumin and shank mouse models of autism. Mol Brain. 2016; 
9(10): 10.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
23.  Donato F, Rompani SB, Caroni P: Parvalbumin-expressing basket-cell 
network plasticity induced by experience regulates adult learning. Nature. 
2013; 504(7479): 272–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
24. Philpot BD, Lim JH, Brunjes PC: Activity-dependent regulation of calcium-
binding proteins in the developing rat olfactory bulb. J Comp Neurol. 1997; 
387(1): 12–26.  
PubMed Abstract | Publisher Full Text 
Page 10 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
25.  Hanno-Iijima Y, Tanaka M, Iijima T: Activity-Dependent Bidirectional 
Regulation of GAD Expression in a Homeostatic Fashion Is Mediated 
by BDNF-Dependent and Independent Pathways. PLoS One. 2015; 10(8): 
e0134296.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
26. Fung SJ, Fillman SG, Webster MJ, et al.: Schizophrenia and bipolar disorder 
show both common and distinct changes in cortical interneuron markers. 
Schizophr Res. 2014; 155(1–3): 26–30.  
PubMed Abstract | Publisher Full Text 
27. Klempan TA, Sequeira A, Canetti L, et al.: Altered expression of genes 
involved in ATP biosynthesis and GABAergic neurotransmission in the 
ventral prefrontal cortex of suicides with and without major depression. Mol 
Psychiatry. 2009; 14(2): 175–89.  
PubMed Abstract | Publisher Full Text 
28. Luscher B, Shen Q, Sahir N: The GABAergic deficit hypothesis of major 
depressive disorder. Mol Psychiatry. 2011; 16(4): 383–406.  
PubMed Abstract | Publisher Full Text | Free Full Text 
29. Guidotti A, Auta J, Davis JM, et al.: Decrease in reelin and glutamic acid 
decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a 
postmortem brain study. Arch Gen Psychiatry. 2000; 57(11): 1061–9.  
PubMed Abstract | Publisher Full Text 
30. Fukata Y, Fukata M: Epilepsy and synaptic proteins. Curr Opin Neurobiol. 2017; 
45(1–8): 1–8.  
PubMed Abstract | Publisher Full Text 
31. Treiman DM: GABAergic mechanisms in epilepsy. Epilepsia. 2001; 42(Suppl 3): 
8–12.  
PubMed Abstract | Publisher Full Text 
32. Symonds C: Excitation and inhibition in epilepsy. Proc R Soc Med. 1959; 52(6): 
395–402.  
PubMed Abstract | Free Full Text 
33. Wong M: Too much inhibition leads to excitation in absence epilepsy. Epilepsy 
Curr. 2010; 10(5): 131–2.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34. Bolton PF, Carcani-Rathwell I, Hutton J, et al.: Epilepsy in autism: features and 
correlates. Br J Psychiatry. 2011; 198(4): 289–94.  
PubMed Abstract | Publisher Full Text | Free Full Text 
35. Tuchman R, Moshé SL, Rapin I: Convulsing toward the pathophysiology of 
autism. Brain Dev. 2009; 31(2): 95–103.  
PubMed Abstract | Publisher Full Text | Free Full Text 
36. Jian L, Nagarajan L, de Klerk N, et al.: Predictors of seizure onset in Rett 
syndrome. J Pediatr. 2006; 149(4): 542–7.  
PubMed Abstract | Publisher Full Text 
37. Amir RE, Van den Veyver IB, Wan M, et al.: Rett syndrome is caused by 
mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Nat 
Genet. 1999; 23(2): 185–8.  
PubMed Abstract | Publisher Full Text 
38. Gelisse P, Samuelian JC, Genton P: Is schizophrenia a risk factor for epilepsy or 
acute symptomatic seizures? Epilepsia. 1999; 40(11): 1566–71.  
PubMed Abstract | Publisher Full Text 
39. Mäkikyrö T, Karvonen JT, Hakko H, et al.: Comorbidity of hospital-treated 
psychiatric and physical disorders with special reference to schizophrenia: a 
28 year follow-up of the 1966 northern Finland general population birth cohort. 
Public Health. 1998; 112(4): 221–8.  
PubMed Abstract 
40. Cascella NG, Schretlen DJ, Sawa A: Schizophrenia and epilepsy: is there a 
shared susceptibility? Neurosci Res. 2009; 63(4): 227–35.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Reilly C, Atkinson P, Das KB, et al.: Neurobehavioral comorbidities in children 
with active epilepsy: a population-based study. Pediatrics. 2014; 133(6):  
e1586–93.  
PubMed Abstract | Publisher Full Text 
42. Williams AE, Giust JM, Kronenberger WG, et al.: Epilepsy and attention-deficit 
hyperactivity disorder: links, risks, and challenges. Neuropsychiatr Dis Treat. 
2016; 12: 287–96.  
PubMed Abstract | Publisher Full Text | Free Full Text 
43. Buzsáki G, Wang XJ: Mechanisms of gamma oscillations. Annu Rev Neurosci. 
2012; 35: 203–25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
44.  Womelsdorf T, Fries P, Mitra PP, et al.: Gamma-band synchronization in 
visual cortex predicts speed of change detection. Nature. 2006; 439(7077): 
733–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
45. Tallon-Baudry C, Bertrand O, Peronnet F, et al.: Induced gamma-band activity 
during the delay of a visual short-term memory task in humans. J Neurosci. 
1998; 18(11): 4244–54.  
PubMed Abstract 
46. Gonzalez-Burgos G, Lewis DA: GABA neurons and the mechanisms of 
network oscillations: implications for understanding cortical dysfunction in 
schizophrenia. Schizophr Bull. 2008; 34(5): 944–61.  
PubMed Abstract | Publisher Full Text | Free Full Text 
47.  Cardin JA, Carlén M, Meletis K, et al.: Driving fast-spiking cells induces 
gamma rhythm and controls sensory responses. Nature. 2009; 459(7247): 
663–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
48.  Sohal VS, Zhang F, Yizhar O, et al.: Parvalbumin neurons and gamma 
rhythms enhance cortical circuit performance. Nature. 2009; 459(7247): 698–702. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
49. Shin YW, O'Donnell BF, Youn S, et al.: Gamma oscillation in schizophrenia. 
Psychiatry Investig. 2011; 8(4): 288–96.  
PubMed Abstract | Publisher Full Text | Free Full Text 
50. Chen CM, Stanford AD, Mao X, et al.: GABA level, gamma oscillation, and 
working memory performance in schizophrenia. Neuroimage Clin. 2014; 4: 
531–9.  
PubMed Abstract | Publisher Full Text | Free Full Text 
51. Farzan F, Barr MS, Levinson AJ, et al.: Evidence for gamma inhibition deficits in 
the dorsolateral prefrontal cortex of patients with schizophrenia. Brain. 2010; 
133(Pt 5): 1505–14.  
PubMed Abstract | Publisher Full Text 
52. Gordon E, Williams L, Haig AR, et al.: Symptom profile and “gamma” processing 
in schizophrenia. Cogn Neuropsychiatry. 2001; 6(1): 7–19.  
Publisher Full Text 
53. Baldeweg T, Spence S, Hirsch SR, et al.: Gamma-band electroencephalographic 
oscillations in a patient with somatic hallucinations. Lancet. 1998; 352(9128): 
620–1.  
PubMed Abstract | Publisher Full Text 
54.  Landau ID, Egger R, Dercksen VJ, et al.: The Impact of Structural 
Heterogeneity on Excitation-Inhibition Balance in Cortical Networks. Neuron. 
2016; 92(5): 1106–21.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
55. Vierling-Claassen D, Siekmeier P, Stufflebeam S, et al.: Modeling GABA 
alterations in schizophrenia: a link between impaired inhibition and altered 
gamma and beta range auditory entrainment. J Neurophysiol. 2008; 99(5): 
2656–71.  
PubMed Abstract | Publisher Full Text | Free Full Text 
56. Uhlhaas PJ, Singer W: Abnormal neural oscillations and synchrony in 
schizophrenia. Nat Rev Neurosci. 2010; 11(2): 100–13.  
PubMed Abstract | Publisher Full Text 
57. Rojas DC, Maharajh K, Teale P, et al.: Reduced neural synchronization of 
gamma-band MEG oscillations in first-degree relatives of children with autism. 
BMC Psychiatry. 2008; 8: 66.  
PubMed Abstract | Publisher Full Text | Free Full Text 
58. Rojas DC, Wilson LB: γ-band abnormalities as markers of autism spectrum 
disorders. Biomark Med. 2014; 8(3): 353–68.  
PubMed Abstract | Publisher Full Text | Free Full Text 
59. Lenz D, Krauel K, Schadow J, et al.: Enhanced gamma-band activity in ADHD 
patients lacks correlation with memory performance found in healthy children. 
Brain Res. 2008; 1235: 117–32.  
PubMed Abstract | Publisher Full Text 
60.  Kamida A, Shimabayashi K, Oguri M, et al.: EEG Power Spectrum Analysis in 
Children with ADHD. Yonago Acta Med. 2016; 59(2): 169–73.  
PubMed Abstract | Free Full Text | F1000 Recommendation 
61. Karch S, Segmiller F, Hantschk I, et al.: Increased γ oscillations during voluntary 
selection processes in adult patients with attention deficit/hyperactivity 
disorder. J Psychiatr Res. 2012; 46(11): 1515–23.  
PubMed Abstract | Publisher Full Text 
62. Yordanova J, Banaschewski T, Kolev V, et al.: Abnormal early stages of task 
stimulus processing in children with attention-deficit hyperactivity disorder-
-evidence from event-related gamma oscillations. Clin Neurophysiol. 2001; 
112(6): 1096–108.  
PubMed Abstract | Publisher Full Text 
63. Özerdem A, Güntekin B, Atagün I, et al.: Reduced long distance gamma (28–48 
Hz) coherence in euthymic patients with bipolar disorder. J Affect Disord. 2011; 
132(3): 325–32.  
PubMed Abstract | Publisher Full Text | Free Full Text 
64.  Stroganova TA, Butorina AV, Sysoeva OV, et al.: Altered modulation of 
gamma oscillation frequency by speed of visual motion in children with 
autism spectrum disorders. J Neurodev Disord. 2015; 7(1): 21.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
65. Petilla Interneuron Nomenclature Group, Ascoli GA, Alonso-Nanclares L, et al.: 
Petilla terminology: nomenclature of features of GABAergic interneurons of 
the cerebral cortex. Nat Rev Neurosci. 2008; 9(7): 557–68.  
PubMed Abstract | Publisher Full Text | Free Full Text 
66. DeFelipe J, López-Cruz PL, Benavides-Piccione R, et al.: New insights into the 
classification and nomenclature of cortical GABAergic interneurons. Nat Rev 
Neurosci. 2013; 14(3): 202–16.  
PubMed Abstract | Publisher Full Text | Free Full Text 
67. Kepecs A, Fishell G: Interneuron cell types are fit to function. Nature. 2014; 
505(7483): 318–26.  
PubMed Abstract | Publisher Full Text | Free Full Text 
68. Rudy B, Fishell G, Lee S, et al.: Three groups of interneurons account for nearly 
100% of neocortical GABAergic neurons. Dev Neurobiol. 2011; 71(1): 45–61. 
PubMed Abstract | Publisher Full Text | Free Full Text 
69.  Pi H, Hangya B, Kvitsiani D, et al.: Cortical interneurons that specialize in 
Page 11 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
disinhibitory control. Nature. 2013; 503(7477): 521–4.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
70. Lee S, Kruglikov I, Huang ZJ, et al.: A disinhibitory circuit mediates motor 
integration in the somatosensory cortex. Nat Neurosci. 2013; 16(11): 1662–70. 
PubMed Abstract | Publisher Full Text | Free Full Text 
71. Fu Y, Tucciarone JM, Espinosa JS, et al.: A cortical circuit for gain control by 
behavioral state. Cell. 2014; 156(6): 1139–52.  
PubMed Abstract | Publisher Full Text | Free Full Text 
72.  Pfeffer CK, Xue M, He M, et al.: Inhibition of inhibition in visual cortex: the 
logic of connections between molecularly distinct interneurons. Nat Neurosci. 
2013; 16(8): 1068–76.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
73.  Jackson J, Ayzenshtat I, Karnani MM, et al.: VIP+ interneurons control 
neocortical activity across brain states. J Neurophysiol. 2016; 115(6): 3008–17. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
74.  Batista-Brito R, Vinck M, Ferguson KA, et al.: Developmental Dysfunction of 
VIP Interneurons Impairs Cortical Circuits. Neuron. 2017; 95(4): 884–895.e9. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
75.  Garcia-Junco-Clemente P, Ikrar T, Tring E, et al.: An inhibitory pull-push 
circuit in frontal cortex. Nat Neurosci. 2017; 20(3): 389–92.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
76.  Vacic V, McCarthy S, Malhotra D, et al.: Duplications of the neuropeptide 
receptor gene VIPR2 confer significant risk for schizophrenia. Nature. 2011; 
471(7339): 499–503.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
77. Chiu CQ, Lur G, Morse TM, et al.: Compartmentalization of GABAergic inhibition 
by dendritic spines. Science. 2013; 340(6133): 759–62.  
PubMed Abstract | Publisher Full Text | Free Full Text 
78. Gentet LJ, Kremer Y, Taniguchi H, et al.: Unique functional properties of 
somatostatin-expressing GABAergic neurons in mouse barrel cortex. Nat 
Neurosci. 2012; 15(4): 607–12.  
PubMed Abstract | Publisher Full Text 
79. Scheyltjens I, Arckens L: The Current Status of Somatostatin-Interneurons in 
Inhibitory Control of Brain Function and Plasticity. Neural Plast. 2016; 2016: 
8723623.  
PubMed Abstract | Publisher Full Text | Free Full Text 
80.  Cichon J, Gan W: Branch-specific dendritic Ca2+ spikes cause persistent 
synaptic plasticity. Nature. 2015; 520(7546): 180–5.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
81.  Fuchs T, Jefferson SJ, Hooper A, et al.: Disinhibition of somatostatin-
positive GABAergic interneurons results in an anxiolytic and antidepressant-
like brain state. Mol Psychiatry. 2017; 22(6): 920–30.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
82. Lin L, Sibille E: Reduced brain somatostatin in mood disorders: a common 
pathophysiological substrate and drug target? Front Pharmacol. 2013; 4: 110. 
PubMed Abstract | Publisher Full Text | Free Full Text 
83.  Veit J, Hakim R, Jadi MP, et al.: Cortical gamma band synchronization 
through somatostatin interneurons. Nat Neurosci. 2017; 20(7): 951–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
84. Bezaire MJ, Soltesz I: Quantitative assessment of CA1 local circuits: knowledge 
base for interneuron-pyramidal cell connectivity. Hippocampus. 2013; 23(9): 
751–85.  
PubMed Abstract | Publisher Full Text | Free Full Text 
85. Hu H, Gan J, Jonas P: Interneurons. Fast-spiking, parvalbumin+ GABAergic 
interneurons: from cellular design to microcircuit function. Science. 2014; 
345(6196): 1255263.  
PubMed Abstract | Publisher Full Text 
86. Nelson SB, Valakh V: Excitatory/Inhibitory Balance and Circuit Homeostasis in 
Autism Spectrum Disorders. Neuron. 2015; 87(4): 684–98.  
PubMed Abstract | Publisher Full Text | Free Full Text 
87. Klausberger T, Somogyi P: Neuronal diversity and temporal dynamics: the unity 
of hippocampal circuit operations. Science. 2008; 321(5885): 53–7.  
PubMed Abstract | Publisher Full Text | Free Full Text 
88. Tricoire L, Pelkey KA, Erkkila BE, et al.: A blueprint for the spatiotemporal 
origins of mouse hippocampal interneuron diversity. J Neurosci. 2011; 31(30): 
10948–70.  
PubMed Abstract | Publisher Full Text | Free Full Text 
89.  Pouille F, Scanziani M: Enforcement of temporal fidelity in pyramidal cells 
by somatic feed-forward inhibition. Science. 2001; 293(5532): 1159–63.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
90. Hu H, Jonas P: A supercritical density of Na+ channels ensures fast signaling 
in GABAergic interneuron axons. Nat Neurosci. 2014; 17(5): 686–93.  
PubMed Abstract | Publisher Full Text | Free Full Text 
91. Ogiwara I, Miyamoto H, Morita N, et al.: Na
v
1.1 localizes to axons of parvalbumin-
positive inhibitory interneurons: a circuit basis for epileptic seizures in mice 
carrying an Scn1a gene mutation. J Neurosci. 2007; 27(22): 5903–14.  
PubMed Abstract | Publisher Full Text 
92. Zaitsev AV, Povysheva NV, Lewis DA, et al.: P/Q-type, but not N-type, calcium 
channels mediate GABA release from fast-spiking interneurons to pyramidal 
cells in rat prefrontal cortex. J Neurophysiol. 2007; 97(5): 3567–73.  
PubMed Abstract | Publisher Full Text 
93.  Bucurenciu I, Kulik A, Schwaller B, et al.: Nanodomain coupling between Ca2+ 
channels and Ca2+ sensors promotes fast and efficient transmitter release at a 
cortical GABAergic synapse. Neuron. 2008; 57(4): 536–45.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
94. Baude A, Bleasdale C, Dalezios Y, et al.: Immunoreactivity for the GABAA 
receptor alpha1 subunit, somatostatin and Connexin36 distinguishes 
axoaxonic, basket, and bistratified interneurons of the rat hippocampus. Cereb 
Cortex. 2007; 17(9): 2094–107.  
PubMed Abstract | Publisher Full Text 
95. Palay SL, Sotelo C, Peters A, et al.: The axon hillock and the initial segment.  
J Cell Biol. 1968; 38(1): 193–201.  
PubMed Abstract | Publisher Full Text | Free Full Text 
96. Somogyi P: A specific ‘axo-axonal’ interneuron in the visual cortex of the rat. 
Brain Res. 1977; 136(2): 345–50.  
PubMed Abstract | Publisher Full Text 
97. Inan M, Blázquez-Llorca L, Merchán-Pérez A, et al.: Dense and overlapping 
innervation of pyramidal neurons by chandelier cells. J Neurosci. 2013; 33(5): 
1907–14.  
PubMed Abstract | Publisher Full Text | Free Full Text 
98. Wang Y, Zhang P, Wyskiel DR: Chandelier Cells in Functional and 
Dysfunctional Neural Circuits. Front Neural Circuits. 2016; 10: 33.  
PubMed Abstract | Publisher Full Text | Free Full Text 
99. Inda MC, Defelipe J, Muñoz A: The distribution of chandelier cell axon terminals 
that express the GABA plasma membrane transporter GAT-1 in the human 
neocortex. Cereb Cortex. 2007; 17(9): 2060–71.  
PubMed Abstract | Publisher Full Text 
100. Cruz DA, Eggan SM, Lewis DA: Postnatal development of pre- and postsynaptic 
GABA markers at chandelier cell connections with pyramidal neurons in 
monkey prefrontal cortex. J Comp Neurol. 2003; 465(3): 385–400.  
PubMed Abstract | Publisher Full Text 
101. Nusser Z, Sieghart W, Benke D, et al.: Differential synaptic localization of 
two major gamma-aminobutyric acid type A receptor alpha subunits on 
hippocampal pyramidal cells. Proc Natl Acad Sci U S A. 1996; 93(21): 11939–44. 
PubMed Abstract | Free Full Text 
102. Nyíri G, Freund TF, Somogyi P: Input-dependent synaptic targeting of alpha2-
subunit-containing GABAA receptors in synapses of hippocampal pyramidal 
cells of the rat. Eur J Neurosci. 2001; 13(3): 428–42.  
PubMed Abstract | Publisher Full Text 
103. Chiu CS, Jensen K, Sokolova I, et al.: Number, density, and surface/cytoplasmic 
distribution of GABA transporters at presynaptic structures of knock-in mice 
carrying GABA transporter subtype 1-green fluorescent protein fusions.  
J Neurosci. 2002; 22(23): 10251–66.  
PubMed Abstract 
104.  Zhu Y, Stornetta RL, Zhu JJ: Chandelier cells control excessive cortical 
excitation: characteristics of whisker-evoked synaptic responses of layer 
2/3 nonpyramidal and pyramidal neurons. J Neurosci. 2004; 24(22): 5101–8. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
105. Ribak CE: Axon terminals of GABAergic chandelier cells are lost at epileptic 
foci. Brain Res. 1985; 326(2): 251–60.  
PubMed Abstract | Publisher Full Text 
106. Defelipe J: Chandelier cells and epilepsy. Brain. 1999; 122(Pt 10): 1807–22. 
PubMed Abstract | Publisher Full Text 
107. Dinocourt C, Petanjek Z, Freund TF, et al.: Loss of interneurons innervating 
pyramidal cell dendrites and axon initial segments in the CA1 region of the 
hippocampus following pilocarpine-induced seizures. J Comp Neurol. 2003; 
459(4): 407–25.  
PubMed Abstract | Publisher Full Text 
108. Woodruff A, Xu Q, Anderson SA, et al.: Depolarizing effect of neocortical 
chandelier neurons. Front Neural Circuits. 2009; 3: 15.  
PubMed Abstract | Publisher Full Text | Free Full Text 
109.  Szabadics J, Varga C, Molnár G, et al.: Excitatory effect of GABAergic  
axo-axonic cells in cortical microcircuits. Science. 2006; 311(5758): 233–5. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
110. Wang X, Hooks BM, Sun QQ: Thorough GABAergic innervation of the entire 
axon initial segment revealed by an optogenetic ‘laserspritzer’. J Physiol. 2014; 
592(19): 4257–76.  
PubMed Abstract | Publisher Full Text | Free Full Text 
111. Woodruff AR, McGarry LM, Vogels TP, et al.: State-dependent function of 
neocortical chandelier cells. J Neurosci. 2011; 31(49): 17872–86.  
PubMed Abstract | Publisher Full Text | Free Full Text 
112. Massi L, Lagler M, Hartwich K, et al.: Temporal dynamics of parvalbumin-
expressing axo-axonic and basket cells in the rat medial prefrontal cortex in 
vivo. J Neurosci. 2012; 32(46): 16496–502.  
PubMed Abstract | Publisher Full Text | Free Full Text 
113. Viney TJ, Lasztoczi B, Katona L, et al.: Network state-dependent inhibition of 
identified hippocampal CA3 axo-axonic cells in vivo. Nat Neurosci. 2013; 16(12): 
1802–11.  
PubMed Abstract | Publisher Full Text | Free Full Text 
114.  Rocco BR, DeDionisio AM, Lewis DA, et al.: Alterations in a Unique Class 
of Cortical Chandelier Cell Axon Cartridges in Schizophrenia. Biol Psychiatry. 
2017; 82(1): 40–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
115. Pierri JN, Chaudry AS, Woo TU, et al.: Alterations in chandelier neuron axon 
Page 12 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
terminals in the prefrontal cortex of schizophrenic subjects. Am J Psychiatry. 
1999; 156(11): 1709–19.  
PubMed Abstract 
116. Schleimer SB, Hinton T, Dixon G, et al.: GABA transporters GAT-1 and GAT-3 in 
the human dorsolateral prefrontal cortex in schizophrenia. Neuropsychobiology. 
2004; 50(3): 226–30.  
PubMed Abstract | Publisher Full Text 
117. Volk D, Austin M, Pierri J, et al.: GABA transporter-1 mRNA in the prefrontal 
cortex in schizophrenia: decreased expression in a subset of neurons. Am J 
Psychiatry. 2001; 158(2): 256–65.  
PubMed Abstract | Publisher Full Text 
118. Volk DW, Pierri JN, Fritschy JM, et al.: Reciprocal alterations in pre- and 
postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons 
in schizophrenia. Cereb Cortex. 2002; 12(10): 1063–70.  
PubMed Abstract 
119. Howard A, Tamas G, Soltesz I: Lighting the chandelier: new vistas for  
axo-axonic cells. Trends Neurosci. 2005; 28(6): 310–6.  
PubMed Abstract | Publisher Full Text 
120. Del Pino I, García-Frigola C, Dehorter N, et al.: Erbb4 deletion from fast-spiking 
interneurons causes schizophrenia-like phenotypes. Neuron. 2013; 79(6): 
1152–68.  
PubMed Abstract | Publisher Full Text 
121. Ting AK, Chen Y, Wen L, et al.: Neuregulin 1 promotes excitatory synapse 
development and function in GABAergic interneurons. J Neurosci. 2011; 31(1): 
15–25.  
PubMed Abstract | Publisher Full Text | Free Full Text 
122. Gibson JR, Bartley AF, Hays SA, et al.: Imbalance of neocortical excitation and 
inhibition and altered UP states reflect network hyperexcitability in the mouse 
model of fragile X syndrome. J Neurophysiol. 2008; 100(5): 2615–26.  
PubMed Abstract | Publisher Full Text | Free Full Text 
123. Seshadri S, Faust T, Ishizuka K, et al.: Interneuronal DISC1 regulates NRG1-
ErbB4 signalling and excitatory-inhibitory synapse formation in the mature 
cortex. Nat Commun. 2015; 6: 10118.  
PubMed Abstract | Publisher Full Text | Free Full Text 
124.  Polepalli JS, Wu H, Goswami D, et al.: Modulation of excitation on 
parvalbumin interneurons by neuroligin-3 regulates the hippocampal network. 
Nat Neurosci. 2017; 20(2): 219–29.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
125.  He LJ, Liu N, Cheng TL, et al.: Conditional deletion of Mecp2 in 
parvalbumin-expressing GABAergic cells results in the absence of critical 
period plasticity. Nat Commun. 2014; 5(1): 5036.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
126. Ji Y, Yang F, Papaleo F, et al.: Role of dysbindin in dopamine receptor 
trafficking and cortical GABA function. Proc Natl Acad Sci U S A. 2009; 106(46): 
19593–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
127. Yu FH, Mantegazza M, Westenbroek RE, et al.: Reduced sodium current in 
GABAergic interneurons in a mouse model of severe myoclonic epilepsy in 
infancy. Nat Neurosci. 2006; 9(9): 1142–9.  
PubMed Abstract | Publisher Full Text 
128.  Fazzari P, Paternain AV, Valiente M, et al.: Control of cortical GABA circuitry 
development by Nrg1 and ErbB4 signalling. Nature. 2010; 464(7293): 1376–80. 
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
129.  Bateup HS, Johnson CA, Denefrio CL, et al.: Excitatory/inhibitory synaptic 
imbalance leads to hippocampal hyperexcitability in mouse models of 
tuberous sclerosis. Neuron. 2013; 78(3): 510–22.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
130. Wallace ML, Burette AC, Weinberg RJ, et al.: Maternal loss of Ube3a produces 
an excitatory/inhibitory imbalance through neuron type-specific synaptic 
defects. Neuron. 2012; 74(5): 793–800.  
PubMed Abstract | Publisher Full Text | Free Full Text 
131.  Lee J, Chung C, Ha S, et al.: Shank3-mutant mice lacking exon 9 show 
altered excitation/inhibition balance, enhanced rearing, and spatial memory 
deficit. Front Cell Neurosci. 2015; 9: 94.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
132.  Won H, Mah W, Kim E, et al.: GIT1 is associated with ADHD in humans and 
ADHD-like behaviors in mice. Nat Med. 2011; 17(5): 566–72.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
133. Rivero O, Selten MM, Sich S, et al.: Cadherin-13, a risk gene for ADHD and 
comorbid disorders, impacts GABAergic function in hippocampus and 
cognition. Transl Psychiatry. 2015; 5: e655.  
PubMed Abstract | Publisher Full Text | Free Full Text 
134. Gibson JR, Huber KM, Südhof TC: Neuroligin-2 deletion selectively decreases 
inhibitory synaptic transmission originating from fast-spiking but not from 
somatostatin-positive interneurons. J Neurosci. 2009; 29(44): 13883–97. 
PubMed Abstract | Publisher Full Text | Free Full Text 
135.  Poulopoulos A, Aramuni G, Meyer G, et al.: Neuroligin 2 drives postsynaptic 
assembly at perisomatic inhibitory synapses through gephyrin and collybistin. 
Neuron. 2009; 63(5): 628–42.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
136.  Földy C, Malenka RC, Südhof TC: Autism-associated neuroligin-3 mutations 
commonly disrupt tonic endocannabinoid signaling. Neuron. 2013; 78(3): 
498–509.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
137. Anderson GR, Galfin T, Xu W, et al.: Candidate autism gene screen identifies 
critical role for cell-adhesion molecule CASPR2 in dendritic arborization and 
spine development. Proc Natl Acad Sci U S A. 2012; 109(44): 18120–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
138.  Xue M, Atallah BV, Scanziani M: Equalizing excitation-inhibition ratios 
across visual cortical neurons. Nature. 2014; 511(7511): 596–600.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
139. Tamás G, Buhl EH, Lörincz A, et al.: Proximally targeted GABAergic synapses 
and gap junctions synchronize cortical interneurons. Nat Neurosci. 2000; 3(4): 
366–71.  
PubMed Abstract | Publisher Full Text 
140.  Taniguchi H, Lu J, Huang ZJ: The spatial and temporal origin of chandelier 
cells in mouse neocortex. Science. 2013; 339(6115): 70–4.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
141. Bartos M, Vida I, Jonas P: Synaptic mechanisms of synchronized gamma 
oscillations in inhibitory interneuron networks. Nat Rev Neurosci. 2007; 8(1): 
45–56.  
PubMed Abstract | Publisher Full Text 
142.  Traub RD, Kopell N, Bibbig A, et al.: Gap junctions between interneuron 
dendrites can enhance synchrony of gamma oscillations in distributed 
networks. J Neurosci. 2001; 21(23): 9478–86.  
PubMed Abstract | F1000 Recommendation 
143.  Mullins C, Fishell G, Tsien RW: Unifying Views of Autism Spectrum 
Disorders: A Consideration of Autoregulatory Feedback Loops. Neuron. 2016; 
89(6): 1131–56.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
144. Turrigiano GG, Leslie KR, Desai NS, et al.: Activity-dependent scaling of quantal 
amplitude in neocortical neurons. Nature. 1998; 391(6670): 892–6.  
PubMed Abstract | Publisher Full Text 
145.  Kilman V, van Rossum MC, Turrigiano GG: Activity deprivation reduces 
miniature IPSC amplitude by decreasing the number of postsynaptic GABA(A) 
receptors clustered at neocortical synapses. J Neurosci. 2002; 22(4): 1328–37. 
PubMed Abstract | F1000 Recommendation 
146. Desai NS, Rutherford LC, Turrigiano GG: Plasticity in the intrinsic excitability of 
cortical pyramidal neurons. Nat Neurosci. 1999; 2(6): 515–20.  
PubMed Abstract | Publisher Full Text 
147. Bartley AF, Huang ZJ, Huber KM, et al.: Differential activity-dependent, 
homeostatic plasticity of two neocortical inhibitory circuits. J Neurophysiol. 
2008; 100(4): 1983–94.  
PubMed Abstract | Publisher Full Text | Free Full Text 
148. Echegoyen J, Neu A, Graber KD, et al.: Homeostatic plasticity studied using in 
vivo hippocampal activity-blockade: synaptic scaling, intrinsic plasticity and 
age-dependence. PLoS One. 2007; 2(8): e700.  
PubMed Abstract | Publisher Full Text | Free Full Text 
149. Norton N, Moskvina V, Morris DW, et al.: Evidence that interaction between 
neuregulin 1 and its receptor erbB4 increases susceptibility to schizophrenia. 
Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(1): 96–101.  
PubMed Abstract | Publisher Full Text 
150. Silberberg G, Darvasi A, Pinkas-Kramarski R, et al.: The involvement of ErbB4 
with schizophrenia: association and expression studies. Am J Med Genet B 
Neuropsychiatr Genet. 2006; 141B(2): 142–8.  
PubMed Abstract | Publisher Full Text 
151. Vullhorst D, Neddens J, Karavanova I, et al.: Selective expression of ErbB4 in 
interneurons, but not pyramidal cells, of the rodent hippocampus. J Neurosci. 
2009; 29(39): 12255–64.  
PubMed Abstract | Publisher Full Text | Free Full Text 
152. Woo RS, Li XM, Tao Y, et al.: Neuregulin-1 enhances depolarization-induced 
GABA release. Neuron. 2007; 54(4): 599–610.  
PubMed Abstract | Publisher Full Text 
153.  Stefansson H, Sigurdsson E, Steinthorsdottir V, et al.: Neuregulin 1 and 
susceptibility to schizophrenia. Am J Hum Genet. 2002; 71(4): 877–92.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
154. Georgieva L, Dimitrova A, Ivanov D, et al.: Support for neuregulin 1 as a 
susceptibility gene for bipolar disorder and schizophrenia. Biol Psychiatry. 
2008; 64(5): 419–27.  
PubMed Abstract | Publisher Full Text 
155. Prata DP, Breen G, Osborne S, et al.: An association study of the neuregulin 1 
gene, bipolar affective disorder and psychosis. Psychiatr Genet. 2009; 19(3): 
113–6.  
PubMed Abstract | Publisher Full Text 
156. Verkerk AJ, Pieretti M, Sutcliffe JS, et al.: Identification of a gene (FMR-1) 
containing a CGG repeat coincident with a breakpoint cluster region exhibiting 
length variation in fragile X syndrome. Cell. 1991; 65(5): 905–14.  
PubMed Abstract | Publisher Full Text 
157. Kaufmann WE, Cortell R, Kau AS, et al.: Autism spectrum disorder in fragile X 
syndrome: communication, social interaction, and specific behaviors. Am J 
Med Genet A. 2004; 129A(3): 225–34.  
PubMed Abstract | Publisher Full Text 
Page 13 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
158. Bear MF, Huber KM, Warren ST: The mGluR theory of fragile X mental 
retardation. Trends Neurosci. 2004; 27(7): 370–7.  
PubMed Abstract | Publisher Full Text 
159. Paluszkiewicz SM, Martin BS, Huntsman MM: Fragile X syndrome: the 
GABAergic system and circuit dysfunction. Dev Neurosci. 2011; 33(5): 349–64. 
PubMed Abstract | Publisher Full Text | Free Full Text 
160. Cea-Del Rio CA, Huntsman MM: The contribution of inhibitory interneurons to 
circuit dysfunction in Fragile X Syndrome. Front Cell Neurosci. 2014; 8: 245. 
PubMed Abstract | Publisher Full Text | Free Full Text 
161. D'Hulst C, De Geest N, Reeve SP, et al.: Decreased expression of the GABAA 
receptor in fragile X syndrome. Brain Res. 2006; 1121(1): 238–45.  
PubMed Abstract | Publisher Full Text 
162. Selby L, Zhang C, Sun QQ: Major defects in neocortical GABAergic inhibitory 
circuits in mice lacking the fragile X mental retardation protein. Neurosci Lett. 
2007; 412(3): 227–32.  
PubMed Abstract | Publisher Full Text | Free Full Text 
163. Gatto CL, Broadie K: Genetic controls balancing excitatory and inhibitory 
synaptogenesis in neurodevelopmental disorder models. Front Synaptic 
Neurosci. 2010; 2: 4.  
PubMed Abstract | Publisher Full Text | Free Full Text 
164.  Krishnan K, Wang BS, Lu J, et al.: MeCP2 regulates the timing of critical 
period plasticity that shapes functional connectivity in primary visual cortex. 
Proc Natl Acad Sci U S A. 2015; 112(34): E4782–91.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
165. Hensch TK: Critical period plasticity in local cortical circuits. Nat Rev Neurosci. 
2005; 6(11): 877–88.  
PubMed Abstract | Publisher Full Text 
166.  Marín O: Developmental timing and critical windows for the treatment of 
psychiatric disorders. Nat Med. 2016; 22(11): 1229–38.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
167.  Chao HT, Chen H, Samaco RC, et al.: Dysfunction in GABA signalling 
mediates autism-like stereotypies and Rett syndrome phenotypes. Nature. 
2010; 468(7321): 263–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
168.  Ito-Ishida A, Ure K, Chen H, et al.: Loss of MeCP2 in Parvalbumin-and 
Somatostatin-Expressing Neurons in Mice Leads to Distinct Rett Syndrome-
like Phenotypes. Neuron. 2015; 88(4): 651–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
169.  Banerjee A, Rikhye RV, Breton-Provencher V, et al.: Jointly reduced 
inhibition and excitation underlies circuit-wide changes in cortical processing 
in Rett syndrome. Proc Natl Acad Sci U S A. 2016; 113(46): E7287–E7296.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
170. Dehorter N, Marichal N, Marín O, et al.: Tuning neural circuits by turning the 
interneuron knob. Curr Opin Neurobiol. 2017; 42: 144–51.  
PubMed Abstract | Publisher Full Text 
171. Beck H, Yaari Y: Plasticity of intrinsic neuronal properties in CNS disorders. 
Nat Rev Neurosci. 2008; 9(5): 357–69.  
PubMed Abstract | Publisher Full Text 
172.  Straub RE, Jiang Y, MacLean CJ, et al.: Genetic variation in the 6p22.3 gene 
DTNBP1, the human ortholog of the mouse dysbindin gene, is associated with 
schizophrenia. Am J Hum Genet. 2002; 71(2): 337–48.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
173. Carlson GC, Talbot K, Halene TB, et al.: Dysbindin-1 mutant mice implicate 
reduced fast-phasic inhibition as a final common disease mechanism in 
schizophrenia. Proc Natl Acad Sci U S A. 2011; 108(43): E962–70.  
PubMed Abstract | Publisher Full Text | Free Full Text 
174.  Larimore J, Zlatic SA, Arnold M, et al.: Dysbindin Deficiency Modifies the 
Expression of GABA Neuron and Ion Permeation Transcripts in the Developing 
Hippocampus. Front Genet. 2017; 8: 28.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
175. Li BM, Liu XR, Yi YH, et al.: Autism in Dravet syndrome: prevalence, features, 
and relationship to the clinical characteristics of epilepsy and mental 
retardation. Epilepsy Behav. 2011; 21(3): 291–5.  
PubMed Abstract | Publisher Full Text 
176.  O'Roak BJ, Deriziotis P, Lee C, et al.: Exome sequencing in sporadic autism 
spectrum disorders identifies severe de novo mutations. Nat Genet. 2011; 
43(6): 585–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
177. Van Wart A, Trimmer JS, Matthews G: Polarized distribution of ion channels 
within microdomains of the axon initial segment. J Comp Neurol. 2007; 500(2): 
339–52.  
PubMed Abstract | Publisher Full Text 
178. Kole MH, Stuart GJ: Signal processing in the axon initial segment. Neuron. 
2012; 73(2): 235–47.  
PubMed Abstract | Publisher Full Text 
179. Cheah CS, Yu FH, Westenbroek RE, et al.: Specific deletion of NaV1.1 sodium 
channels in inhibitory interneurons causes seizures and premature death in 
a mouse model of Dravet syndrome. Proc Natl Acad Sci U S A. 2012; 109(36): 
14646–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
180. Dutton SB, Makinson CD, Papale LA, et al.: Preferential inactivation of Scn1a in 
parvalbumin interneurons increases seizure susceptibility. Neurobiol Dis. 2013; 
49: 211–20.  
PubMed Abstract | Publisher Full Text | Free Full Text 
181. Han S, Tai C, Westenbroek RE, et al.: Autistic-like behaviour in Scn1a+/- mice 
and rescue by enhanced GABA-mediated neurotransmission. Nature. 2012; 
489(7416): 385–90.  
PubMed Abstract | Publisher Full Text | Free Full Text 
182.  Stedehouder J, Kushner SA: Myelination of parvalbumin interneurons: a 
parsimonious locus of pathophysiological convergence in schizophrenia. Mol 
Psychiatry. 2017; 22(1): 4–12.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
183. White T, Magnotta VA, Bockholt HJ, et al.: Global white matter abnormalities in 
schizophrenia: a multisite diffusion tensor imaging study. Schizophr Bull. 2011; 
37(1): 222–32.  
PubMed Abstract | Publisher Full Text | Free Full Text 
184. Uranova NA, Vostrikov VM, Orlovskaya DD, et al.: Oligodendroglial density in 
the prefrontal cortex in schizophrenia and mood disorders: a study from the 
Stanley Neuropathology Consortium. Schizophr Res. 2004; 67(2–3): 269–75. 
PubMed Abstract | Publisher Full Text 
185. Hakak Y, Walker JR, Li C, et al.: Genome-wide expression analysis reveals 
dysregulation of myelination-related genes in chronic schizophrenia. Proc Natl 
Acad Sci U S A. 2001; 98(8): 4746–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
186. Katsumaru H, Kosaka T, Heizmann CW, et al.: Immunocytochemical study of 
GABAergic neurons containing the calcium-binding protein parvalbumin in the 
rat hippocampus. Exp Brain Res. 1988; 72(2): 347–62.  
PubMed Abstract | Publisher Full Text
187.  Micheva KD, Wolman D, Mensh BD, et al.: A large fraction of neocortical 
myelin ensheathes axons of local inhibitory neurons. eLife. 2016; 5: pii: e15784. 
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
188.  Chung K, Wallace J, Kim SY, et al.: Structural and molecular interrogation of 
intact biological systems. Nature. 2013; 497(7449): 332–7.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
189. Nave KA, Werner HB: Myelination of the nervous system: mechanisms and 
functions. Annu Rev Cell Dev Biol. 2014; 30: 503–33.  
PubMed Abstract | Publisher Full Text 
190. Lewis DA: The chandelier neuron in schizophrenia. Dev Neurobiol. 2011; 71(1): 
118–27.  
PubMed Abstract | Publisher Full Text | Free Full Text 
191.  Del Pino I, Brotons-Mas JR, Marques-Smith A, et al.: Abnormal wiring of 
CCK+ basket cells disrupts spatial information coding. Nat Neurosci. 2017; 
20(6): 784–92.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
192. Prather P, de Vries PJ: Behavioral and cognitive aspects of tuberous sclerosis 
complex. J Child Neurol. 2004; 19(9): 666–74.  
PubMed Abstract | Publisher Full Text 
193. Jones AC, Shyamsundar MM, Thomas MW, et al.: Comprehensive mutation 
analysis of TSC1 and TSC2-and phenotypic correlations in 150 families with 
tuberous sclerosis. Am J Hum Genet. 1999; 64(5): 1305–15.  
PubMed Abstract | Publisher Full Text | Free Full Text 
194. Rougeulle C, Glatt H, Lalande M: The Angelman syndrome candidate gene, 
UBE3A/E6-AP, is imprinted in brain. Nat Genet. 1997; 17(1): 14–5.  
PubMed Abstract | Publisher Full Text 
195. Williams CA, Beaudet AL, Clayton-Smith J, et al.: Angelman syndrome 2005: 
updated consensus for diagnostic criteria. Am J Med Genet A. 2006; 140(5): 
413–8.  
PubMed Abstract | Publisher Full Text 
196. Thibert RL, Conant KD, Braun EK, et al.: Epilepsy in Angelman syndrome: a 
questionnaire-based assessment of the natural history and current treatment 
options. Epilepsia. 2009; 50(11): 2369–76.  
PubMed Abstract | Publisher Full Text 
197. Jiang YH, Armstrong D, Albrecht U, et al.: Mutation of the Angelman ubiquitin 
ligase in mice causes increased cytoplasmic p53 and deficits of contextual 
learning and long-term potentiation. Neuron. 1998; 21(4): 799–811.  
PubMed Abstract | Publisher Full Text 
198. Yashiro K, Riday TT, Condon KH, et al.: Ube3a is required for experience-
dependent maturation of the neocortex. Nat Neurosci. 2009; 12(6): 777–83. 
PubMed Abstract | Publisher Full Text | Free Full Text 
199.  Judson MC, Wallace ML, Sidorov MS, et al.: GABAergic Neuron-Specific 
Loss of Ube3a Causes Angelman Syndrome-Like EEG Abnormalities and 
Enhances Seizure Susceptibility. Neuron. 2016; 90(1): 56–69.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
200.  Wallace ML, van Woerden GM, Elgersma Y, et al.: Ube3a loss increases 
excitability and blunts orientation tuning in the visual cortex of Angelman 
syndrome model mice. J Neurophysiol. 2017; 118(1): 634–46.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
201.  Atallah BV, Bruns W, Carandini M, et al.: Parvalbumin-expressing 
interneurons linearly transform cortical responses to visual stimuli. Neuron. 
2012; 73(1): 159–70.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
202.  Wilson NR, Runyan CA, Wang FL, et al.: Division and subtraction by distinct 
Page 14 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
cortical inhibitory networks in vivo. Nature. 2012; 488(7411): 343–8.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
203. Leblond CS, Nava C, Polge A, et al.: Meta-analysis of SHANK Mutations in 
Autism Spectrum Disorders: a gradient of severity in cognitive impairments. 
PLoS Genet. 2014; 10(9): e1004580.  
PubMed Abstract | Publisher Full Text | Free Full Text 
204. Monteiro P, Feng G: SHANK proteins: roles at the synapse and in autism 
spectrum disorder. Nat Rev Neurosci. 2017; 18(3): 147–57.  
PubMed Abstract | Publisher Full Text 
205. Naisbitt S, Kim E, Tu JC, et al.: Shank, a novel family of postsynaptic density 
proteins that binds to the NMDA receptor/PSD-95/GKAP complex and 
cortactin. Neuron. 1999; 23(3): 569–82.  
PubMed Abstract | Publisher Full Text 
206.  Tao-Cheng J, Yang Y, Reese TS, et al.: Differential distribution of Shank 
and GKAP at the postsynaptic density. PLoS One. 2015; 10(3): e0118750.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
207.  Peça J, Feliciano C, Ting JT, et al.: Shank3 mutant mice display autistic-like 
behaviours and striatal dysfunction. Nature. 2011; 472(7344): 437–42.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
208.  Bozdagi O, Sakurai T, Papapetrou D, et al.: Haploinsufficiency of the 
autism-associated Shank3 gene leads to deficits in synaptic function, social 
interaction, and social communication. Mol Autism. 2010; 1(1): 15.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
209.  Wang X, McCoy PA, Rodriguiz RM, et al.: Synaptic dysfunction and 
abnormal behaviors in mice lacking major isoforms of Shank3. Hum Mol Genet. 
2011; 20(15): 3093–108.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
210. Südhof TC: Neuroligins and neurexins link synaptic function to cognitive 
disease. Nature. 2008; 455(7215): 903–11.  
PubMed Abstract | Publisher Full Text | Free Full Text 
211.  Chih B, Engelman H, Scheiffele P: Control of excitatory and inhibitory 
synapse formation by neuroligins. Science. 2005; 307(5713): 1324–8.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
212. Song JY, Ichtchenko K, Südhof TC, et al.: Neuroligin 1 is a postsynaptic cell-
adhesion molecule of excitatory synapses. Proc Natl Acad Sci U S A. 1999; 
96(3): 1100–5.  
PubMed Abstract | Publisher Full Text | Free Full Text 
213.  Varoqueaux F, Jamain S, Brose N: Neuroligin 2 is exclusively localized to 
inhibitory synapses. Eur J Cell Biol. 2004; 83(9): 449–56.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
214. Budreck EC, Scheiffele P: Neuroligin-3 is a neuronal adhesion protein at 
GABAergic and glutamatergic synapses. Eur J Neurosci. 2007; 26(7): 1738–48. 
PubMed Abstract | Publisher Full Text 
215. Hoon M, Soykan T, Falkenburger B, et al.: Neuroligin-4 is localized to glycinergic 
postsynapses and regulates inhibition in the retina. Proc Natl Acad Sci U S A. 
2011; 108(7): 3053–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
216.  Jamain S, Quach H, Betancur C, et al.: Mutations of the X-linked genes 
encoding neuroligins NLGN3 and NLGN4 are associated with autism. Nat 
Genet. 2003; 34(1): 27–9.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
217.  Tabuchi K, Blundell J, Etherton MR, et al.: A neuroligin-3 mutation implicated 
in autism increases inhibitory synaptic transmission in mice. Science. 2007; 
318(5847): 71–6.  
PubMed Abstract | Publisher Full Text | Free Full Text | F1000 Recommendation 
218.  Hammer M, Krueger-Burg D, Tuffy LP, et al.: Perturbed Hippocampal 
Synaptic Inhibition and γ-Oscillations in a Neuroligin-4 Knockout Mouse Model 
of Autism. Cell Rep. 2015; 13(3): 516–23.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
219.  Parente DJ, Garriga C, Baskin B, et al.: Neuroligin 2 nonsense variant 
associated with anxiety, autism, intellectual disability, hyperphagia, and 
obesity. Am J Med Genet A. 2017; 173(1): 213–6.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
220. Sun C, Cheng MC, Qin R, et al.: Identification and functional characterization 
of rare mutations of the neuroligin-2 gene (NLGN2) associated with 
schizophrenia. Hum Mol Genet. 2011; 20(15): 3042–51.  
PubMed Abstract | Publisher Full Text | Free Full Text 
221. Kim HG, Kishikawa S, Higgins AW, et al.: Disruption of neurexin 1 associated 
with autism spectrum disorder. Am J Hum Genet. 2008; 82(1): 199–207.  
PubMed Abstract | Publisher Full Text | Free Full Text 
222. Kirov G, Gumus D, Chen W, et al.: Comparative genome hybridization suggests 
a role for NRXN1 and APBA2 in schizophrenia. Hum Mol Genet. 2008; 17(3): 
458–65.  
PubMed Abstract | Publisher Full Text 
223. Kirov G, Rujescu D, Ingason A, et al.: Neurexin 1 (NRXN1) deletions in 
schizophrenia. Schizophr Bull. 2009; 35(5): 851–4.  
PubMed Abstract | Publisher Full Text | Free Full Text 
224. Etherton MR, Blaiss CA, Powell CM, et al.: Mouse neurexin-1alpha deletion 
causes correlated electrophysiological and behavioral changes consistent 
with cognitive impairments. Proc Natl Acad Sci U S A. 2009; 106(42): 17998–8003.  
PubMed Abstract | Publisher Full Text | Free Full Text 
225. Rabaneda LG, Robles-Lanuza E, Nieto-González JL, et al.: Neurexin dysfunction 
in adult neurons results in autistic-like behavior in mice. Cell Rep. 2014; 8(2): 
338–46.  
PubMed Abstract | Publisher Full Text 
226. de la Peña JB, Dela Peña IJ, Custodio RJ, et al.: Exploring the Validity of 
Proposed Transgenic Animal Models of Attention-Deficit Hyperactivity 
Disorder (ADHD). Mol Neurobiol. 2017; 1–16.  
PubMed Abstract | Publisher Full Text 
227. Salatino-Oliveira A, Genro JP, Chazan R, et al.: Association study of GIT1 
gene with attention-deficit hyperactivity disorder in Brazilian children and 
adolescents. Genes Brain Behav. 2012; 11(7): 864–8.  
PubMed Abstract | Publisher Full Text 
228.  Klein M, van der Voet M, Harich B, et al.: Converging evidence does not 
support GIT1 as an ADHD risk gene. Am J Med Genet B Neuropsychiatr Genet. 
2015; 168(6): 492–507.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
229. Smith KR, Davenport EC, Wei J, et al.: GIT1 and βPIX are essential for GABAA 
receptor synaptic stability and inhibitory neurotransmission. Cell Rep. 2014; 
9(1): 298–310.  
PubMed Abstract | Publisher Full Text | Free Full Text 
230. Arias-Vásquez A, Altink ME, Rommelse NN, et al.: CDH13 is associated with 
working memory performance in attention deficit/hyperactivity disorder. Genes 
Brain Behav. 2011; 10(8): 844–51.  
PubMed Abstract | Publisher Full Text 
231. Zhou K, Dempfle A, Arcos-Burgos M, et al.: Meta-analysis of genome-wide 
linkage scans of attention deficit hyperactivity disorder. Am J Med Genet B 
Neuropsychiatr Genet. 2008; 147B(8): 1392–8.  
PubMed Abstract | Publisher Full Text | Free Full Text 
232. Rivero O, Sich S, Popp S, et al.: Impact of the ADHD-susceptibility gene CDH13 
on development and function of brain networks. Eur Neuropsychopharmacol. 
2013; 23(6): 492–507.  
PubMed Abstract | Publisher Full Text 
233. Killen AC, Barber M, Paulin JJW, et al.: Protective role of Cadherin 13 in 
interneuron development. Brain Struct Funct. 2017; 222(8): 3567–3585.  
PubMed Abstract | Publisher Full Text | Free Full Text 
234. Benarroch EE: GABAB receptors: structure, functions, and clinical implications. 
Neurology. 2012; 78(8): 578–84.  
PubMed Abstract | Publisher Full Text 
235. Lüscher C, Jan LY, Stoffel M, et al.: G protein-coupled inwardly rectifying K+ 
channels (GIRKs) mediate postsynaptic but not presynaptic transmitter 
actions in hippocampal neurons. Neuron. 1997; 19(3): 687–95.  
PubMed Abstract | Publisher Full Text 
236. Ikeda SR: Voltage-dependent modulation of N-type calcium channels by  
G-protein beta gamma subunits. Nature. 1996; 380(6571): 255–8.  
PubMed Abstract | Publisher Full Text 
237. Mintz IM, Bean BP: GABAB receptor inhibition of P-type Ca2+ channels in central 
neurons. Neuron. 1993; 10(5): 889–98.  
PubMed Abstract | Publisher Full Text 
238. Mizukami K, Sasaki M, Ishikawa M, et al.: Immunohistochemical localization 
of gamma-aminobutyric acidB receptor in the hippocampus of subjects with 
schizophrenia. Neurosci Lett. 2000; 283(2): 101–4.  
PubMed Abstract | Publisher Full Text 
239. Mizukami K, Ishikawa M, Hidaka S, et al.: Immunohistochemical localization 
of GABAB receptor in the entorhinal cortex and inferior temporal cortex of 
schizophrenic brain. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26(2): 
393–6.  
PubMed Abstract | Publisher Full Text 
240. Ishikawa M, Mizukami K, Iwakiri M, et al.: Immunohistochemical and immunoblot 
analysis of gamma-aminobutyric acid B receptor in the prefrontal cortex of 
subjects with schizophrenia and bipolar disorder. Neurosci Lett. 2005; 383(3): 
272–7.  
PubMed Abstract | Publisher Full Text 
241. Fatemi SH, Folsom TD, Thuras PD: Deficits in GABAB receptor system in 
schizophrenia and mood disorders: a postmortem study. Schizophr Res. 2011; 
128(1–3): 37–43.  
PubMed Abstract | Publisher Full Text | Free Full Text 
242. Selten MM, Meyer F, Ba W, et al.: Increased GABAB receptor signaling in a rat 
model for schizophrenia. Sci Rep. 2016; 6: 34240.  
PubMed Abstract | Publisher Full Text | Free Full Text 
243. Wierońska JM, Kusek M, Tokarski K, et al.: The GABAB receptor agonist 
CGP44532 and the positive modulator GS39783 reverse some behavioural 
changes related to positive syndromes of psychosis in mice. Br J Pharmacol. 
2011; 163(5): 1034–47.  
PubMed Abstract | Publisher Full Text | Free Full Text 
244.  Wierońska JM, Kłeczek N, Woźniak M, et al.: mGlu5-GABAB interplay in 
animal models of positive, negative and cognitive symptoms of schizophrenia. 
Neurochem Int. 2015; 88: 97–109.  
PubMed Abstract | Publisher Full Text | F1000 Recommendation 
245. Turrigiano GG: The dialectic of Hebb and homeostasis. Philos Trans R Soc Lond 
B Biol Sci. 2017; 372(1715): pii: 20160258.  
PubMed Abstract | Publisher Full Text | Free Full Text 
Page 15 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
 Open Peer Review
  Current Referee Status:
Editorial Note on the Review Process
 are commissioned from members of the prestigious   and are edited as aF1000 Faculty Reviews F1000 Faculty
service to readers. In order to make these reviews as comprehensive and accessible as possible, the referees
provide input before publication and only the final, revised version is published. The referees who approved the
final version are listed with their names and affiliations but without their reports on earlier versions (any comments
will already have been addressed in the published version).
The referees who approved this article are:
Version 1
The benefits of publishing with F1000Research:
Your article is published within days, with no editorial bias
You can publish traditional articles, null/negative results, case reports, data notes and more
The peer review process is transparent and collaborative
Your article is indexed in PubMed after passing peer review
Dedicated customer support at every stage
For pre-submission enquiries, contact   research@f1000.com
 Department of Integrative Neurophysiology, Center for Neurogenomics and CognitiveRhiannon Meredith
Research, Amsterdam Neuroscience, Vrije Universiteit, Amsterdam, Netherlands
 No competing interests were disclosed.Competing Interests:
1
 Department of Neurology, FM Kirby Neurobiology Center, Boston Children's Hospital,Hisashi Umemori
Harvard Medical School, Boston, USA
 No competing interests were disclosed.Competing Interests:
1
Page 16 of 16
F1000Research 2018, 7(F1000 Faculty Rev):23 Last updated: 08 JAN 2018
